S-Adenosyl-L-methionine (SAMe): From the bench to the bedside - Molecular basis of a pleiotrophic molecule

American Journal of Clinical Nutrition

Volumn 76, Issue 5, 2002, Pages

  Bottiglieri, Teodoro ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dementia; Depression; Liver disease; Methylation; Osteoarthritis; S Adenosylmethionine; SAMe; Vacuolar myelopathy

Indexed keywords

IMIPRAMINE; MINAPRINE; NOMIFENSINE; S ADENOSYLMETHIONINE;

ARTICLE; CELL METABOLISM; DEMENTIA; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG METABOLISM; HUMAN; LIVER DISEASE; METHYLATION; NONHUMAN; OSTEOARTHRITIS; RAT; SPINAL CORD DISEASE;

EID: 0036828353     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/76.5.1151s     Document Type: Article

References (81)

1. Cantoni GL. The nature of the active methyl donor formed enzymatically from L-methionine and adenosine triphosphate. J Am Chem Soc 1952;74:2942-3.
2. Cheng X, Blumenthal RM. S-Adenosylmethionine-Dependent Methyltransferases: Structures and Functions. World Scientific Publication Co, 1999.
3. Chiang PK, Gordon RK, Tal J, et al. S-Adenosylmethionine and methylation. FASEB J 1996;10:471-80.
4. Janicak PG, Lipinski JD, Comaty JE, et al. S-Adenosylmethionine: A literature review and preliminary report. Ala J Med Sci 1988;25: 306-13.
5. Friedel HA, Goa KL, Benfield P. S-Adenosyl-L-methionine: A review of its therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416.
6. Bressa GM. S-Adenosyl-L-methionine (SAMe) as antidepressant: Meta-analysis of clinical studies. Acta Neurol Scand 1994;154:7-14.
7. Bradley JD, Flusser D, Katz BP, et al. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol 1994;21:905-11.
8. Padova C. S-Adenosylmethionine in the treatment of osteoarthritis: Review of the clinical studies. Am J Med 1987;83:60-5.
9. Lieber CS. Role of S-adenosyl-L-methionine in the treatment of liver diseases. J Hepatol 1999;30:1155-9.
10. Williams R, Lieber CS. The role of SAMe in the treatment of liver disease. Drugs 1990;40(suppl):1-2.
11. Mato JM, Camara J, Fernandez de Paz J, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-9.
12. Brown R, Gerbarg P, Bottiglieri T. S-Adenosylmethionine in the clinical practice of psychiatry, neurology and internal medicine. Clin Pract Intern Med 2000;1:230-41.
13. Paulsen M, Ferguson-Smith AC. DNA methylation in genomic imprinting, development, and disease. J Pathol 2001;195:97-110.
14. Momparler RL, Bovenci V. DNA methylation and cancer. J Cell Physiol 2000;183:145-54.
15. Billingsley ML, Balaban CD. Protein-O-carboxylmethyltransferase in the rat brain: High regional levels in the substantia nigra, locus coeruleus and paraventricular nucleus. Brain Res 1985;358:96-103.
16. Clarke S. Perspectives on the biological function and enzymology of protein carboxyl methylation reactions in eucaryotic and procaryotic cells. Adv Exp Med Biol 1988;231:213-28.
17. Hirata F, Viveros OH, Diliberto EJ Jr, Axelrod J. Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine. Proc Natl Acad Sci U S A 1978;75:1718-21.
18. Crews FT. Effects of membrane fluidity on secretion and receptor stimulation. Psychopharmacol Bull 1982;18:135-43.
19. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997;20:55-66.
20. Cheng H, Gomes-Trolin C, Aquilonius SM, et al. Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp Neurol 1997;145:580-5.
21. Surtees R, Hyland K. L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. J Neurol Neurosurg Psychiatry 1990;53:569-72.
22. Taylor KM, Randall PK. Depletion of S-adenosyl-L-methionine in mouse brain by antidepressive drugs. J Pharmacol Exp Ther 1975;194:303-10.
23. Mudd SH, Pool JH. Labile methyl balances from normal humans on various dietary regimens. Metabolism 1975;24:721-35.
24. Finkelstein JD, Martin JJ, Harris BJ. Methionine metabolism in mammals. The methionine-sparing effect of cystine. J Biol Chem 1988;263:11750-4.
25. Womack M, Rose WC. Partial replacement of dietary methionine by cysteine for purposes of growth. J Biol Chem 1941;141:375-9.
26. Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. J Biol Chem 1984;259:9508-13.
27. Della Ragione F, Pegg AE. Effect of analogues of 5′-methylthioadenosine on cellular metabolism. Inactivation of S-adenosylhomocysteine hydrolase by 5′-isobutylthioadenosine. Biochem J 1983;210:429-35.
28. Herby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981;19:1-20.
29. Oyanagui Y. Anti-inflammatory effects of polyamines in serotonin and carrageenan paw edemata - Possible mechanism to increase vascular permeability inhibitory protein level which is regulated by glucocorticoids and superoxide radical. Agents Actions 1984;14:228-37.
30. Stramentinoli G, Gualano M, Galli-Kienle M. Intestinal absorption of S-adenosyl-L-methionine. J Pharmacol Exp Ther 1979;209:323-6.
31. Bottiglieri T, Chary TKN, Laundy M, et al. Transmethylation and depression. Ala J Med Sci 1988;25:296-300.
32. Stramentinoli G. Ademethionine as a drug. Am J Med 1987; 83(suppl):35-42.
33. Giulidori P, Fellin M, Di Padova C. Metabolism of exogenous S-adenosylmethionine in humans and its significance in the therapeutic use of the drug. Proceedings of the Workshop Methionine Metabolism: Molecular Mechanisms and Clinical Implications. Madrid, Spain: Jarpyo Editores, 1998:159-63.
34. Bottiglieri T, Chary TKN, Carney MWP, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: The effect of parenteral and oral treatment. J Neurol Neurosurg Psychiatry 1990;53:1096-8.
35. Castagna A, Le Grazie C, Giulidori P, Bottiglieri T, Lazzarin A. Deficiency of CSF S-adenosylmethionine (SAMe) and glutathione in HIV infected patients: The effect of parenteral treatment with SAMe. Neurology 1995;45:1678-83.
36. Zappia V, Galletti P, Porcelli M, Ruggiero G, Andreana A. Uptake of adenosylmethionine and related sulfur compounds by isolated rat liver. FEBS Lett 1978;90:331-5.
37. Horne DW, Holloway RS, Wagner C. Transport of S-adenosylmethionine in isolated rat liver mitochondria. Arch Biochem Biophys 1997;343:201-6.
38. Fazio C, Andreoli V, Agnoli A, Casacchia M, Cerbo R. Therapeutic effects and mechanism of action of S-adenosyl-L-methionine (SAM) in depressive syndromes. Minerva Med 1973;64:1515-29.
39. Bottiglieri T. Folate, vitamin B 12, and neuropsychiatric disorders. Nutr Rev 1996;54:382-90.
40. Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders. Clinical potential. Drugs 1993;45:623-36.
41. Chen Z, Karaplis AC, Ackerman SL, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001;10:433-43.
42. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-32.
43. Algeri S, Catto E, Curcio M, Ponzio F, Stramentinoli G. Changes in rat brain noradrenaline and serotonin after administration of S-adenosylmethionine. In: Zappia V, Usdin E, Salvatore S, eds. Biochemical and Pharmacological Roles of Adenosylmethionine and the Central Nervous System. New York: Pergamon Press, 1979:81-7.
44. Otero-Losado ME, Rubio MC. Acute effects of S-adenosyl-L-methionine on catecholaminergic central function. Eur J Pharmacol 1989;163:353-6.
45. Otero-Losado ME, Rubio MC. Acute changes in 5HT metabolism after S-adenosylmethionine administration. Gen Pharmacol 1989;20:403-6.
46. Curcio M. Catto E, Stramentinoli G, Algeri S. Effect of SAMe on 5HT metabolism in rat brain. Prog Neuropsychopharmacol 1978;2:65-71.
47. Bottiglieri T, Laundy M, Martin R, et al. S-Adenosylmethionine influences monoamine metabolism. Lancet 1984;2:224.
48. Cimino M, Vantini G, Algeri S, Curala G, Pezzoli C, Stramentinoli G. Age-related modification of dopaminergic and beta-adrenergic receptor system: Restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Sci 1984;34:2029-39.
49. Muccioli G, Scordamaglia A, Bertacco S, Di Carlo R. Effect of S-adenosyl-L-methionine on brain muscarinic receptors. Eur J Pharmacol 1992;227:293-9.
50. Kowatch MA, Roth GS. Effect of specific membrane perturbations on alpha-adrenergic and muscarinic-cholinergic signal transduction in rat parotid cell aggregates. Life Sci 1994;55:2003-10.
51. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 1996;67:1328-31.
52. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 1992;89:1671-5.
53. Cuenod CA, Kaplan DB, Michot JL, et al. Phospholipid abnormalities in early Alzheimer's disease. In vivo phosphorus 31 magnetic resonance spectroscopy. Arch Neurol 1995;52:89-94.
54. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-55.
55. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 2001;56:1188-94.
56. Bottiglieri T, Parnetti L, Arning E, et al. Plasma total homocysteine levels and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene: A study in an Italian population with dementia. Mech Ageing Dev 2001;122:2013-23.
57. Reynolds EH, Godfrey P, Bottiglieri T, et al. S-Adenosylmethionine in the treatment of Alzheimer's disease. Neurology 1989;39(suppl): 397 (abstr).
58. Nilsson Knopman D, Patterson M. An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 2001;15:162-5.
59. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry 2001;16:609-14.
60. Passeri M, Cucinotta D, Abate G, et al. Oral 5′-methyltetrahydrofolic acid in senile organic mental disorders with depression: Results of a double-blind multicenter study. Aging (Milano) 1993;5:63-71.
61. Surtees R, Leonard J, Austin S. Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet 1991;338:1550-4.
62. Surtees R, Hyland K, Smith I. Central-nervous-system methyl-group metabolism in children with neurological complications of HIV infection. Lancet 1990;335:619-21.
63. Keating JN, Trimble KC, Mulcahy F, Scott JM, Weir DG. Evidence of brain methyltransferase inhibition and early brain involvement in HIV-positive patients. Lancet 1991;337:935-9.
64. Tan SV, Guiloff RJ. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. J Neurol Neurosurg Psychiatry 1998;65:23-8.
65. Petito CK, Navia BA, Cho ES, et al. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985;312:874-9.
66. Goggins M, Scott JM, Weir DG. Methylation of cortical brain proteins from patients with HIV infection. Acta Neurol Scand 1999;100:326-31.
67. Horowitz JH, Rypins EB, Henderson JM, et al. Evidence for impairment of transsulfuration pathway in cirrhosis. Gastroenterology 1981;81:668-75.
68. Duce AM, Ortiz P, Cabrero C, Mato JM. S-Adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 1988;8:65-8.
69. Ruiz F, Corrales FJ, Miqueo C, Mato JM. Nitric oxide inactivates rat hepatic methionine adenosyltransferase in vivo by S-nitrosylation. Hepatology 1998;28:1051-7.
70. Corrales FJ, Ruiz F, Mato JM. In vivo regulation by glutathione of methionine adenosyltransferase S-nitrosylation in rat liver. J Hepatol 1999;31:887-94.
71. Loguercio C, Nardi G, Argenzio F, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol Alcohol 1994;29:597-604.
72. Galan AI, Munoz ME, Palomero J, Moreno C, Jimenez R. Role of S-adenosylmethionine on the hepatobiliary homeostasis of glutathione during cyclosporine A treatment. J Physiol Biochem 2000;56:189-200.
73. Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989;24:407-15.
74. Lieber CS. Alcoholic liver disease: New insights in pathogenesis lead to new treatments. J Hepatol 2000;32(suppl):113-28.
75. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-Adenosylmethionine synthesis: Molecular mechanisms and clinical implications. Pharmacol Ther 1997;73:265-80.
76. Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiatr Res 1976;13:43-54.
77. Di Padova C. S-Adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med 1987;83:60-5.
78. Harmand MF, Vilamitjana J, Maloche E, Duphil R, Ducassou D. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. An in vitro study. Am J Med 1987;83:48-54.
79. Barcelo HA, Wiemeyer JC, Sagasta CL, Macias M, Barreira JC, Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits. Am J Med 1987;83:55-9.
80. Vittur F, Lunazzi G, Moro L, et al. A possible role for polyamines in cartilage in the mechanism of calcification. Biochim Biophys Acta 1986;881:38-45.
81. Gutierrez S, Palacios I, Sanchez-Pernaute O, et al. SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells. Br J Rheumatol 1997;36:27-31.